Российское диализное общество

Просмотр статьи

<< Вернуться к списку статей журнала

Том 5 №1 2003 год - Нефрология и диализ

Проблемы вакцинопрофилактики гепатита В в условиях лечения программным гемодиализом


Зубкин М.Л.

Аннотация: Заместительная терапия терминальной стадии хронической почечной недостаточности (тХПН), особенно программный гемодиализ (ПГД), относится к факторам риска инфицирования вирусами гепатитов с преимущественно парентеральным путем заражения. Мировой опыт свидетельствует о том, что в период лечения ПГД, в зависимости от регионов, стран и даже отдельных диализных центров, заболеваемость вирусными гепатитами колеблется в широком диапазоне - от 15 до 80%.

Весь текст



Ключевые слова: хроническая почечная недостаточность, гемодиализ, вирусные гепатиты, вакцинопрофилактика, иммунодефицит

Список литературы:
  1. Зубкин М.Л., Селиванов Н.А., Стаханова В.М. и др. Распространенность и особенности инфицирования вирусами гепатитов В и С в условиях лечения гемодиализом. Вопр. вирусол. 2000; 1: 10-14.
  2. Зубкин М.Л., Селькова Е.П., Стаханова В.М. и др. Гепатит В в центрах гемодиализа Москвы: клинико-эпидемиологическая характеристика. Нефрология и диализ 2001; 4: 442-446.
  3. Ивашкин В.Т., Калинин А.В., Ивлев А.С. и др. Распространенность вирусов гепатитов В и С среди доноров крови, больных и медицинского персонала. Российский журнал гастроэнтерологии, гепатологии и колопроктологии. 1993; 2: 34-38.
  4. Кожокарь Ю.В. Клинико-эпидемиологическая характеристика гепатита В у больных с терминальной стадией хронической почечной недостаточности в условиях лечения программным гемодиализом; особенности вакцинопрофилактики: Автореф. дисс.. канд. мед. наук. М., 2000.
  5. Майер К.П. Гепатит и последствия гепатита. М.: Гэотар Медицина, 1999: 51-54.
  6. Савин Е.А. Вирусные гепатиты (частные аспекты проблемы). Санкт-Петербург: Наука, 1996: 85-94, 115-120.
  7. Тареев Е.М., Ермоленко В.М., Ананьев В.А. и др. Вирусные гепатиты у больных, находящихся на поддерживающем ГД. Особенности клиники. Вопросы эпидемиологии. Вестник АМН СССР. 1979; 4: 20-26.
  8. Alter M.J., Favero M.S., Maynard J.E. Impact of infection control strategies on the incidence of dialysis-associated hepatitis in the United States. J Infect Dis 1986; 153: 1149-1151.
  9. Beaman M., Michael J., Maclennan I.C., Adu D. T cell independent and T cell dependent antibody response in patients with chronic renal failure. Nephrol Dial Transplant 1989; 4: 216-221.
  10. Bergia R., Pellerey M., Berto I. et al. Hepatitis B Vaccination in Uremic Patients: Comparison beetween Recombinant and Plasma-Derived Vaccine. Nephron 1992; 61: 328.
  11. Cappel R., Van Beers D., Liesnard C., Dratwa M. Impaired humoral and cell-mediated immune responses in dialyzed patients after influenza vaccination. Nephron 1983; 33: 21-25.
  12. Casciani C.U., de Simone C., Bonini S. et al. Immunological aspects of chronic uremia. Kidney Int 1978; S45-S54.
  13. Colombo M., Choo Q.L., Del Ninno E. et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989; 334: 1006-1009.
  14. Crosnier J., Degos F., Jungers P. Dialysis associated hepatitis. In: Replacement of renal function by dialysis (ed. Maher J.F.) Dordrecht: Kluwer Academic, 1989: 881-903.
  15. Debure A., Degos F., Pol S. et al. Liver disease and hepatic complications infection in renal transplant patients. Adv Nephrol 1988; 17: 375-400.
  16. Department of Health Advisory Group on Hepatitis. Protecting health care workers and patients from hepatitis B. Recommendations of the Advisory Group on Hepatitis. HMSO, London. 1993.
  17. Descamps-Latscha B. Infection and immunity in end-stage renal disease. In: Dialysis (ed. Henrich W.L.) Baltimore, Philadelphia, Hong Kong: Williams & Wilkins. 1994: 209-224.
  18. Dilek K., Dilek S., Ersoy A. et al. Factors influencing response to hepatitis B vaccination of haemodialysis patients and timing of additional booster doses. XXXIV-th Congress ERA EDTA, Geneva. 1997.
  19. Doherty C.C., Girndt M., Gerken G., Kohler H. The patient with failing renal function. Hepatitis. In: Oxford Textbook of Clinical Nephrology. (ed. Davison A.M., Cameron J.S., Grunfeld J.-P. et al.) Oxford, New York, Tokyo: Oxford University Press. 1998: 1924-1935.
  20. Dummin G.J., Couch N.P., Murray J.E. Prolonged survival of skin gomografts in uremic patients. Ann NY Acad Sci 1957; 64: 967-976.
  21. Dusheiko G., Hoofnagle J.H. In: Oxford Textbook of Clinical Hepatology (ed. McIntyre N., Benhamou J.-P., Bircher J., Rizzetto M., Rodes J.). Oxford: Oxford University Press. 1991; 571-592.
  22. Garson J.A., Brillanti S., Ring C. et al: Hepatitis С viraemia rebound after «successful» interferon therapy in patients with chronic non-A, non-B hepatitis. J Med Virol 1992; 37: 210-214.
  23. Gerez L., Madar L., Shkolnik T. et al. Regulation of interleikin-2 and interferon-γ gene expression in renal failure. Kidney Int 1991; 40: 266-272.
  24. Gerlich W.H., Thomssen R. Terminology, structure and laboratory diagnosis of hepatitis viruses. In: Oxford Textbook of Clinical Hepatology (ed. McIntyre N., Benhamou J.-P., Bircher J., Rizzetto M., Rodes J.). Oxford: Oxford University Press. 1991; 537-565.
  25. Girndt M., Heisel O., Kohler H. Influence of dialysis with polyamide versus hemophane hemodialysis on monokines and complement activation during a four month long-term study. Nephrol Dial Transplant 1999; 14: 676-682.
  26. Girndt M., Kohler H., Schiedhelm Weick E. et al. Production of interleukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int 1995; 47: 559-565.
  27. Girndt M., Kohler H., Schiedhelm-Weick E. et al. T-cell activation defect in hemodialysis patients: Evidence for a role of the B7/CD28 pathway. Kidney Int 1993; 44: 359-365.
  28. Girndt M., Kohler H. Hepatitis B Virus Infection in Hemodialysis Patients. Seminars in Nephrology 2002; 4: 340-350.
  29. Girndt M., Sester M., Sester U. et al. Defective expression of B7-2 (CD86) on monocytes of dialysis patients correlates to the uremia-associated immune defect. Kidney Int 2001; 59: 1382-1389.
  30. Girndt M., Sester U., Sester M. et al. The interleukin-10 promotor genotype determines clinical immune function in hemodialysis patients. Kidney Int 2001; 60: 2385-2391.
  31. Girndt M., Trumpfheller C., Hunger F. et al. Reduced expression of B7-molecules on monocytes of hemodialysis patients is involved in impaired T-cell activation. J Am Soc Nephrol 1994; 5: 748.
  32. Hadziyannis S.J. Hepatocellular carcinoma and type B hepatitis. Clin in Gastroenterol 1980; 9: 117-134.
  33. Hall A.J. Hepatitis B vaccination: protection for how long and against what? Brit Med J 1993; 307: 176-177.
  34. Haubitz M., Ehlerding G., Beigel A. et al. Clinical experience with a new recombinant hepatitis-B vaccine in previous non-responders with chronic renal insufficiency. Clin Nephrol 1996; 45: 180-182.
  35. Henry J., Miller M.M., Pontaroitti P. Structure and evolution of the extended B7 family. Immunol Today 1999; 20: 285-288.
  36. Hess G., Kreiter F., Kosters W., Deusch K. The effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on hepatitis B vaccination in haemodialysis patients. J Viral Hepat 1996; 3: 149-153.
  37. Holodniy M., Katzenstein D.A., Israelski D.M. el al. Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction. J Clin Invest 1991; 88: 1755-1759.
  38. Jalava Т., Ranki M., Bengtstrom M. et al. A rapid and quantitative solution hybridization method for detection of HBV DNA in serum. J Virol Methods 1992; 36: 171-180.
  39. Jilg W., Schmidt M., Deinhardt F. Persistence of specific antibodies after hepatitis B vaccination. J Hepatol 1988; 6: 201-207.
  40. Jungers P., Chauveau P., Loubaris T. et al. Immune response to hepatitis B vaccine in chronic uremic patients. In: Progress in hepatitis B immunization (ed. Coursaget P. and Tong M.J.), Colloque INSERM, John Libbey Eurotext. 1990; 194: 187-195.
  41. Jungers P., Devillier P., Salomon H. et al. Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uremic patients who are non-responders to hepatitis B vaccine. Lancet 1994; 344: 856-857.
  42. Kalayci C., Johnson P.J., Davis S.E., Williams R. Hepatitis B virus related hepatocellular carcinoma in the non-cirrhotic liver. Hepatology 1991; 12: 54-59.
  43. Kaperonis N. et al. Long-term effectiveness of intradermal vs intramuscular vaccination against hepatitis B in hemodialysis patients. XXXVI Congress of the European Renal Association European Dialysis and Transplant Association, Madrid, Spain. 1999; 236.
  44. Kapoor D., Aggarwal S.R., Singh N.P. et al. Granulocyte-macrophage colony-stimulating factor enhances the efficacy of hepatitis B virus vaccine in previously unvaccinated hemodialysis patients. J Viral Hepat 1999; 6: 405-409.
  45. Kaul H., Girndt M., Sester U. el al. Initiation of hemodialysis treatment leads to improvement of T cell activation in patients with end stage renal diseases. Am J Kidney Dis 2000; 5: 611-614.
  46. Kayatas M., Akalin L., Ozdemir F.N. et al. Levamisole treatment enhances protective antibody response to hepatitis В virus vaccination (HBVV). 34th Congress ERA-EDTA. Geneva. 1997; 173.
  47. Khan A.N., Bernardini J., Rault R.M., Piraino B. Low seroconversion with hepatitis B vaccination in peritoneal dialysis patients. Perit Dial Int 1996; 16: 370-373.
  48. Kohler H. Hepatitis B immunisation in dialysis patients is it worthwhide? Nephrol Dial Transplant 1994; 9: 1719-1720.
  49. Kurz P., Kohler H., Meuer S. et al. Impaired cellular immune responses in chronic renal failure: evidence for a T cell defect. Kidney Int 1986; 29: 1209-1213.
  50. Liu Y., Linsley P.S. Costimulation of T cell growth. Current Opin in Immunol 1992; 4: 265-270.
  51. Lonnemann G., Linnenweber S., Burg M. et al. Transfer of endogenous pyrogens across artificial membranes? Kidney Int Suppl 1998; 66: 43-46.
  52. Marangi A.L., Giordano R., Montanaro A. et al. Hepatitis B virus infection in chronic uremia: long-term follow-up of a two-step integrated protocol of vaccination. Am I Kidney Dis 1994; 23: 537-542.
  53. Martinov S., Kugaevskaya A., Kopyrina E. et al. Hepatitis virus infection in haemodialysis patients in Sakha Republic (Yakutia). XXXVI Congress of the European Renal Association European Dialysis and Transplant. Association, Madrid, Spain. 1999; 216.
  54. McAdam A.J., Schweitzer A.N., Sharpe A.H. The role of B7 costimulation in activation and differentiation of CD4+ and СD8+-Т cells. Immunol Rev 1998; 165: 231-247.
  55. Meuer S.C., Hauer M., Kurz P. et al. Selective blockade of the antigen-receptor-mediated pathway of T cell activation in patients with impaired immune responses. J Clin Investig 1987; 80: 743-749.
  56. Meuer S.C., Dumann H., Meyer zum Buschenfelde K.H., Kohler H. Low-dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination. Lancet 1989; i: 15-18.
  57. Miller K.D., Gibbs R.D., Mulligan M.M. et al. Intradermal hepatitis B virus vaccine: immunogenicity and side-effects in adults. Lancet 1983; 2: 1454-1456.
  58. Mitwalli A. Responsiveness to hepatitis B vaccine in immunocompromised patients by doubling the dose scheduling. Nephron 1996; 73: 417-420.
  59. Morgan D.R. (ed.) for the British Medical Association Board of Science and Education. A code of practice for implementation of the UK hepatitis B immunisation guidelines for the protection of patients and staff. London: British Medical Association, 1995.
  60. Morita Y., Yamamura M., Kashihara N. et al. Increased production of iterleukin-10 and inflammatory cytokines in blood monocytes of hemodialysis patients. Res Comuiun Mol Pathol Pharmacol 1997; 98: 19-33.
  61. Navarro J.F., Teruel J.L., Mateos M.L. et al. Antibody level after hepatitis B vaccination in hemodialysis patients: influence of hepatitis C virus infection. Am J Nephrol 1996; 16: 95-97.
  62. Neilson J.O., Dietrichson O., Elling P., Christofferson P. Incidence and meaning of persistence of Australian antigen in patients with acute viral hepatitis: development of chronic hepatitis. N Engl J Med 1971; 285: 1157-1159.
  63. Neto M.C., Draibe S.A., Silva A.E.B. et al. Incidence of and risk factors for hepatitis B virus and hepatitis C virus infection among hemodialysis and CAPD patients: evidence for environmental transmission. Nephrol Dial Transplant 1995; 10: 240-246.
  64. Ono K., Kashiwagi S. Complete seroconversion by low-dose intradermal injection of recombinant hepatitis B vaccine in haemodialysis patients. Nephron 1991; 58: 47-51.
  65. Parfrey P.S., Farge D., Forbes R.D.C. et al. Chronic hepatitis in end-stage renal disease: Comparison of HbsAg-negative and HBsAg-positive patients. Kidney Int 1985; 28: 959-967.
  66. Peces R., de la Torre M., Alcazar R., Urra J.M. Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in haemodialysis patients. Am J Kidney Dis 1997; 29: 239-245.
  67. Pertosa G., Tarantino E.A., Gesualdo L. et al. C5b-9 generation and cytokine production in hemodialyzed patients. Kidney Int Suppl 1993; 41: 221-225.
  68. Rao V.K., Ma J. Chronic viral hepatitis enhances the risk of infection but not acute rejection in renal transplant recipients. Transplantation 1996; 62: 1765-1769.
  69. Ribot S., Rolhstein M., Goldblat M. et al. Duration of hepatitis В surface antigenemia (HBsAg) in hemodialysis patients. Arch Intern Med 1979; 139: 178-180.
  70. Scheierniann N., Thraenhart O., Dermietzel R. et al. Permeability of dialysis membranes for hepatitis-B virus: On the prophylaxis of hepatitis in a hemodialysis centre. Dtsch Med Wochenschr 1977; 102: 10-13.
  71. Schindler R., Lonnemann G., Schaffer J. et al. The effect of ultrafiltered dialysate on the cellular content of interleukin-1 receptor antagonist in patients on chronic hemodialysis. Nephron 1994; 68: 229-233.
  72. Schusterman N., Singer I. Infectious hepatitis in dialysis patients. Amer J Kidney Dis 1987; 9: 447-455.
  73. Schweitzer A.N., Sharpe A.H. Studies using antigen-presenting cells lacking expression of both B7-1 (CD80) and B7-2(CD86) show distinct requirements for B7 molecules during priming versus restimulation of Th2 but not Th1 cytokine production. J Immunol 1998; 161: 2762-2771.
  74. Sherlock S., Dooley J. Diseases of the liver and biliary system. Oxford, London, Edinburg, Malden: Blackwell Science Ltd 1997: 274-335.
  75. Tokars J.L., Alter M.J., Favero M.S. et al. National surveillance of dialysis associated diseases in the United States, 1993. ASAIO J 1996; 42: 219-229.
  76. Tremolada F., Casarin C., Alberti A. et al. Long-term follow-up of non-A, non-B (type C) posttransfusion hepatitis. Hepatology 1992; 16: 273-281.
  77. Tokars J.I., Arduino M.J., Alter M.J. Infection control in hemodialysis units. Infect Dis Clin North Am 2001; 15: 797-812.
  78. Vlassopoulos D., Arvanitis D., Lilis D. et al. Complete success of intradermal vaccination against hepatitis B in advanced chronic renal failure and hemodialysis patients. Ren Fail 1997; 19: 455-460.
  79. Wilson W.E.C., Kirkpatrick C.H.H., Talmadge D.W. Suppression of immunologic responsiveness in uremia. Ann Intern Med 1965; 62: 1-8.
  80. Wright T.L, Lau J.Y. Clinical aspects of hepatitis B virus infection. Lancet 1993; 342: 1340-1344.
  81. Younossi M.Z., Braun E.W., Protiva A.D. et al. Chronic viral hepatitis in renal transplant recipients with allografts functioning for more 20 years. Transplantation 1999; 67: 272-275.
  82. Zoulek G., Lorbeer B., Jilg W., Deinhardt F. Evaluation of a reduced dose of hepatitis B vaccine administered intradermally. J Med Virol 1984; 14: 27-38.
  83. Zuckerman J.N. Hepatitis В third-generation vaccines: improved response and conventional vaccine non-response - third generation pre-S/S vaccines overcome non-response. J Viral Hepat 1998; 5: 13-15.

Другие статьи по теме


Навигация по статьям
Разделы журнала
Наиболее читаемые статьи
Журнал "Нефрология и диализ"